Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	epithelial ovarian cancer
ICD-0-3	C56.9
Methods	Microarray, qPCR, Western blot, Luciferase reporter assay etc.
Sample	epithelial ovarian cancer tissues, cell lines (SKOV3, SKOV3.ip, HO8910 and HO8910-PM)
Expression Pattern	up-regulated
Function Description	We verified RAD51-AS1 as a target of E2F1 under negative regulation in EOC. We then examined RAD51-AS1 expression in EOC samples using in situ hybridization (ISH). RAD51-AS1 was localized to the nucleus and found to be a critical marker for clinical features that significantly correlated with poor survival in EOC patients. RAD51-AS1 was also an independent prognostic factor for EOC. Overexpression of RAD51-AS1 promoted EOC cell proliferation, while silencing of RAD51-AS1 inhibited EOC cell proliferation, delayed cell cycle progression and promoted apoptosis in vitro and in vivo. RAD51-AS1 may participate in carcinogenesis via regulation of p53 and p53-related genes. Our study highlights the role of RAD51-AS1 as a prognostic marker of EOC. Survival analysis showed that EOC patients with high RAD51-AS1 expression levels had a significantly decreased overall survival (OS) than those with low RAD51-AS1 expression levels.
Pubmed ID	28667302
Year	2017
Title	E2F1-regulated long non-coding RNA RAD51-AS1 promotes cell cycle progression, inhibits apoptosis and predicts poor prognosis in epithelial ovarian cancer.

External Links